- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01072396
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Kingston, Ontario, Canadá
- 205.440.2003 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá
- 205.440.2001 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 205.440.2004 Boehringer Ingelheim Investigational Site
-
Ste-Foy, Quebec, Canadá
- 205.440.2002 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
- 205.440.1006 Boehringer Ingelheim Investigational Site
-
Jasper, Alabama, Estados Unidos
- 205.440.1015 Boehringer Ingelheim Investigational Site
-
-
California
-
Torrance, California, Estados Unidos
- 205.440.1002 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos
- 205.440.1018 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Springfield, Illinois, Estados Unidos
- 205.440.1008 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Muncie, Indiana, Estados Unidos
- 205.440.1017 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Livonia, Michigan, Estados Unidos
- 205.440.1020 Boehringer Ingelheim Investigational Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos
- 205.440.1011 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos
- 205.440.1019 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos
- 205.440.1013 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Spartanburg, South Carolina, Estados Unidos
- 205.440.1007 Boehringer Ingelheim Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
For COPD subjects: Male or female, age of 40 years or older, smoking history >10 pack-years, symptomatic defined as baseline dyspnea index focal score of 9 or more and / or daily cough with production of sputum for three months per year during at least two consecutive years, diagnosis of early stage COPD according to: post-bronchodilator FEV1/FVC ratio <70%., FEV1 >/=50% post-bronchodilator predicted normal, and a decreased Inspiratory Capacity during exercise. For Age / Gender Matched Controls: Male or female, age of 40 years or older, nonsmoker, with no significant diseases.
Exclusion criteria:
Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.
Patients with a history of asthma, Patients requiring the use of supplemental oxygen therapy, Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris, claudication or other conditions, or Patients with contraindications to exercise.
Note: Additional exclusion criteria for Age / Gender Matched Controls: Patients with a significant disease including COPD.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: 18 mcg tiotropium
Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
|
double blind randomized crossover
|
Comparador de placebos: Placebo
Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
|
inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
|
Sin intervención: Control
Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change From Baseline in Inspiratory Capacity (IC) at Isotime
Periodo de tiempo: baseline, six weeks of treatment
|
Inspiratory capacity (IC) during CWR exercise testing measured at isotime (isotime was established during CWR exercise testing at baseline).
Isotime is the minimum exercise time among all tests.
Constant work rate exercise means the exercise is done under constant work rate.
|
baseline, six weeks of treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Constant Work Rate (CWR) Endurance Time
Periodo de tiempo: six weeks of treatment
|
CWR exercise duration calculated as the length of time of the exercise period
|
six weeks of treatment
|
Change From Baseline in Modified Borg Scale Ratings for Dyspnea Intensity at Isotime
Periodo de tiempo: baseline, six weeks of treatment
|
Modified Borg Scale is a participant rating of the intensity of dyspnea measured on a scale ranging from 0 (Nothing at all) to 10 (Maximal, most severe ever experienced).
|
baseline, six weeks of treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Publicaciones Generales
- Gagnon P, Casaburi R, Saey D, Porszasz J, Provencher S, Milot J, Bourbeau J, O'Donnell DE, Maltais F. Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease. PLoS One. 2015 Apr 23;10(4):e0123626. doi: 10.1371/journal.pone.0123626. eCollection 2015.
- Porszasz J, Blonshine S, Cao R, Paden HA, Casaburi R, Rossiter HB. Biological quality control for cardiopulmonary exercise testing in multicenter clinical trials. BMC Pulm Med. 2016 Jan 16;16:13. doi: 10.1186/s12890-016-0174-8.
- Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, Paden HA, O'Donnell DE; 205.440 Investigators. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014 Nov;11(9):1351-61. doi: 10.1513/AnnalsATS.201404-174OC.
- O'Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, Deng Q, Iqbal A, Paden HA, Casaburi R; 205.440 investigators. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS One. 2014 May 1;9(5):e96574. doi: 10.1371/journal.pone.0096574. eCollection 2014.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Enfermedades Pulmonares Obstructivas
- Enfermedad Pulmonar Obstructiva Crónica
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Parasimpaticolíticos
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Antagonistas colinérgicos
- Agentes colinérgicos
- Agentes broncodilatadores
- Agentes antiasmáticos
- Agentes del sistema respiratorio
- Bromuro de tiotropio
Otros números de identificación del estudio
- 205.440
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tiotropium
-
Imperial College LondonBoehringer IngelheimTerminadoEPOC | ENFERMEDADES PULMONARES OBSTRUCTIVASReino Unido